Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Year: 2018
Type: article
Study design: Clinical Trial
Source: The Lancet Respiratory Medicine
Institutions: University of Siena, Instituto Nazionale Tumori Regina Elena
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Tumori Foundation
OpenAlex ID: W2801062708
